ATE205535T1 - Chemerische immunogene - Google Patents

Chemerische immunogene

Info

Publication number
ATE205535T1
ATE205535T1 AT93901988T AT93901988T ATE205535T1 AT E205535 T1 ATE205535 T1 AT E205535T1 AT 93901988 T AT93901988 T AT 93901988T AT 93901988 T AT93901988 T AT 93901988T AT E205535 T1 ATE205535 T1 AT E205535T1
Authority
AT
Austria
Prior art keywords
protein
piv
rsv
gene sequence
pathogen
Prior art date
Application number
AT93901988T
Other languages
English (en)
Inventor
Michel H Klein
Run-Pan Du
Mary E Ewasyshyn
Original Assignee
Aventis Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pasteur filed Critical Aventis Pasteur
Application granted granted Critical
Publication of ATE205535T1 publication Critical patent/ATE205535T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/115—Paramyxoviridae, e.g. parainfluenza virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/115—Paramyxoviridae, e.g. parainfluenza virus
    • G01N2333/135—Respiratory syncytial virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT93901988T 1992-01-06 1993-01-05 Chemerische immunogene ATE205535T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929200117A GB9200117D0 (en) 1992-01-06 1992-01-06 Production of recombinant chimeric proteins for vaccine use
PCT/CA1993/000001 WO1993014207A1 (en) 1992-01-06 1993-01-05 Chimeric immunogens

Publications (1)

Publication Number Publication Date
ATE205535T1 true ATE205535T1 (de) 2001-09-15

Family

ID=10708117

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93901988T ATE205535T1 (de) 1992-01-06 1993-01-05 Chemerische immunogene

Country Status (16)

Country Link
US (13) US6225091B1 (de)
EP (1) EP0621898B1 (de)
JP (1) JP3290662B2 (de)
KR (1) KR100208310B1 (de)
AT (1) ATE205535T1 (de)
AU (1) AU667502B2 (de)
CA (1) CA2126863C (de)
DE (1) DE69330745T2 (de)
DK (1) DK0621898T3 (de)
ES (1) ES2164070T3 (de)
FI (1) FI117514B (de)
GB (1) GB9200117D0 (de)
NO (1) NO316622B1 (de)
PT (1) PT621898E (de)
RU (1) RU2123047C1 (de)
WO (1) WO1993014207A1 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9200117D0 (en) * 1992-01-06 1992-02-26 Connaught Lab Production of recombinant chimeric proteins for vaccine use
US6479055B1 (en) 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
FR2718452B1 (fr) 1994-04-06 1996-06-28 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
US6300090B1 (en) 1994-07-29 2001-10-09 The Rockefeller University Methods of use of viral vectors to deliver antigen to dendritic cells
US20030054505A1 (en) * 1997-09-26 2003-03-20 Hong Jin Recombinant rsv expression systems and vaccines
FR2726472B1 (fr) 1994-11-07 1997-01-31 Pf Medicament Proteine porteuse a effet adjuvant, complexe immunogene la contenant, leur procede de preparation, sequence nucleotidique et vaccin
US7485440B2 (en) 1995-09-27 2009-02-03 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
EP0912724B1 (de) 1996-07-15 2009-12-09 The Government of The United States of America, as represented by The Department of Health and Human Services Herstellung von attenuierten respiratorischen syncytialvirus-impfstoffen aus klonierten nukleotidsequenzen
US6699476B1 (en) 1996-07-15 2004-03-02 Peter L. Collins Production of recombinant respiratory syncytial viruses expressing immune modulatory molecules
FR2751229B1 (fr) * 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins
US20030082209A1 (en) 2000-07-05 2003-05-01 Skiadopoulos Mario H. Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines
US7632508B2 (en) 1997-05-23 2009-12-15 The United States Of America Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines
US7201907B1 (en) 1997-05-23 2007-04-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Attenuated human-bovine chimeric parainfluenza virus(PIV) vaccines
US7192593B2 (en) * 1997-05-23 2007-03-20 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of recombinant parainfluenza viruses (PIVs) as vectors to protect against infection and disease caused by PIV and other human pathogens
US7314631B1 (en) 1997-05-23 2008-01-01 The United States Of America As Represented By The Department Of Health And Human Services Use of recombinant live-attenuated parainfluenza virus (PIV) as a vector to protect against disease caused by PIV and respiratory syncytial virus (RSV)
US7951383B2 (en) 1997-05-23 2011-05-31 The United States Of America As Represented By The Department Of Health And Human Services Attenuated parainfluenza virus (PIV) vaccines
US7250171B1 (en) 1997-05-23 2007-07-31 United States Of America As Represented By The Dept. Of Health & Human Services Construction and use of recombinant parainfluenza viruses expressing a chimeric glycoprotein
US6410023B1 (en) 1997-05-23 2002-06-25 United States Of America Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene
US6258782B1 (en) * 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6656906B1 (en) * 1998-05-20 2003-12-02 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
AU5980899A (en) * 1998-09-25 2000-04-17 Smithkline Beecham Biologicals (Sa) Novel compounds
CA2378661A1 (en) * 1999-07-09 2001-01-18 Alexander C. Schmidt Attenuated human-bovine chimeric parainfluenza virus (piv) vaccines
CN101260386A (zh) 1999-07-09 2008-09-10 美国政府健康及人类服务部 减毒的人-牛嵌合呼吸道合胞病毒疫苗的生产
US6764685B1 (en) 2000-03-21 2004-07-20 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines
US20030232055A1 (en) * 2000-07-31 2003-12-18 Ruslan Medzhitov Innate immune system-directed vaccines
US20030175287A1 (en) * 2001-01-03 2003-09-18 Yale University Innate immune system-directed vaccines
DK1351981T3 (da) 2001-01-19 2012-11-26 Vironovative Bv Et virus, der forårsager luftvejssygdom hos modtagelige pattedyr
US8715922B2 (en) 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
US20040096451A1 (en) * 2002-07-25 2004-05-20 Young James F. Methods of treating and preventing RSV, hMPV, and PIV using anti-RSV, anti-hMPV, and anti-PIV antibodies
TWI344991B (en) 2002-02-21 2011-07-11 Medimmune Vaccines Inc Metapneumovirus strains as vaccine formulations and as vectors for expression of heterologous antigenic sequences
US7402427B2 (en) * 2002-04-30 2008-07-22 Dnavec Research Inc. Vectors with modified protease-dependent tropism
WO2004066961A2 (en) * 2003-01-20 2004-08-12 St. Jude Children's Research Hospital Use of sendai virus as a human parainfluenza vaccine
WO2004087062A2 (en) * 2003-03-28 2004-10-14 Medimmune Vaccines, Inc. Compositions and methods involving respiratory syncytial virus subgroup b strain 9320
CN101410519B (zh) 2003-04-25 2013-04-24 免疫医疗有限责任公司 间质肺病毒株及其在疫苗制剂中以及用作抗原性序列表达载体的用途和繁殖病毒的方法
AR052195A1 (es) * 2005-01-19 2007-03-07 Vaxinnate Corp Composiciones de patrones moleculares asociados a patogenos en metodos de uso
ES2555544T3 (es) 2006-03-07 2016-01-04 Vaxinnate Corporation Composiciones que incluyen hemaglutinina, métodos de preparación y métodos de uso de las mismas
DE102006060799A1 (de) 2006-12-21 2008-06-26 RUHR-UNIVERSITäT BOCHUM RSV F-Protein und seine Verwendung
EP2391383B1 (de) 2009-02-02 2015-12-23 ChronTech Pharma AB Codon-optimiertes hepatitis b virus core antigen (hbcag)
SG176807A1 (en) * 2009-06-24 2012-01-30 Id Biomedical Corp Quebec Vaccine
EP2668282A2 (de) * 2011-01-28 2013-12-04 MedImmune, LLC Expression löslicher viraler fusionsglykoproteine in säugetierzellen
US9463236B2 (en) 2011-08-29 2016-10-11 Tokushima University RSV mucosal vaccine
WO2013082500A2 (en) * 2011-12-02 2013-06-06 Rhode Island Hospital Vaccine for falciparum malaria
SI2879702T1 (sl) 2012-08-01 2020-02-28 Bavarian Nordic A/S Cepivo na osnovi rekombinantnega modificiranega virusa vakcinacije Ankara (MVA) proti respiratornemu sincitialnemu virusu (RSV)
WO2014186409A1 (en) 2013-05-15 2014-11-20 Chrontech Pharma Ab Immunogenic compositions for inhibiting hepatitis d virus
DE20164728T1 (de) 2015-10-22 2021-09-30 Modernatx, Inc. Impfstoffe gegen atemwegsvirus
EP3551193A4 (de) 2016-12-08 2020-08-19 Modernatx, Inc. Nukleinsäureimpstoffe gegen atemwegsvirus
WO2018170347A1 (en) 2017-03-17 2018-09-20 Modernatx, Inc. Zoonotic disease rna vaccines
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
WO2026092136A1 (en) * 2024-10-28 2026-05-07 Sichuan Clover Biopharmaceuticals, Inc. Combo vaccines for respiratory diseases

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5110587A (en) * 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US4722848A (en) * 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4866034A (en) * 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
SE8205892D0 (sv) * 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
EP0175261B1 (de) * 1984-09-12 1991-12-11 Chiron Corporation Hybridpartikel-Immunogene
AU576907B2 (en) * 1984-11-01 1988-09-08 American Home Products Corporation Oral vaccines comprising live recombinant adenoviruses
US4722898A (en) * 1985-04-29 1988-02-02 Minnesota Mining And Manufacturing Company Immobilization of biological cells in polytetrafluoroethylene matrix
GB8610983D0 (en) * 1986-05-06 1986-06-11 Connaught Lab Enhancement of antigen immunogenicity
US4879213A (en) * 1986-12-05 1989-11-07 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse
US5098998A (en) * 1987-04-29 1992-03-24 President And Fellows Of Harvard College Cholera vaccines and peptides
EP0316695B1 (de) * 1987-11-16 1993-03-31 F. Hoffmann-La Roche Ag Rekombinante HIV-2 Polypeptide
WO1989005823A1 (en) * 1987-12-23 1989-06-29 The Upjohn Company Chimeric glycoproteins containing immunogenic segments of the glycoproteins of human respiratory syncytial virus
US5169628A (en) * 1988-04-22 1992-12-08 The Upjohn Company Chimeric glycoproteins containing immunogenic segments of human parainfluenza virus type 3
FR2636842B1 (fr) 1988-09-27 1994-06-10 Liege Universite Etat Proteine de fusion d'une sequence derivee de la sous-unite b de la toxine cholerique et d'un antigene heterologue doue de proprietes immunogenes, compositions de vaccins les contenant et acides nucleiques recombinants contenant une sequence de nucleotides codant pour ladite proteine de fusion
EP0421626A1 (de) 1989-09-19 1991-04-10 Merck & Co. Inc. Vakzin gegen AIDS und Hepatitis B
GB9200117D0 (en) * 1992-01-06 1992-02-26 Connaught Lab Production of recombinant chimeric proteins for vaccine use
IL105456A (en) 1992-04-21 1996-12-05 American Home Prod Vaccines of attenuated respiratory syncytial virus

Also Published As

Publication number Publication date
GB9200117D0 (en) 1992-02-26
ES2164070T3 (es) 2002-02-16
DE69330745T2 (de) 2002-05-29
RU94042722A (ru) 1996-09-10
US7514535B2 (en) 2009-04-07
DK0621898T3 (da) 2001-11-12
US5998169A (en) 1999-12-07
FI117514B (fi) 2006-11-15
US20080311624A1 (en) 2008-12-18
US7498153B2 (en) 2009-03-03
US6225091B1 (en) 2001-05-01
US6168786B1 (en) 2001-01-02
US7671186B2 (en) 2010-03-02
EP0621898B1 (de) 2001-09-12
US20080032342A1 (en) 2008-02-07
US20080015340A1 (en) 2008-01-17
JPH07501707A (ja) 1995-02-23
US7405273B2 (en) 2008-07-29
PT621898E (pt) 2002-03-28
CA2126863A1 (en) 1993-07-22
KR100208310B1 (ko) 1999-07-15
FI943211A0 (fi) 1994-07-05
US7619063B2 (en) 2009-11-17
NO316622B1 (no) 2004-03-15
JP3290662B2 (ja) 2002-06-10
FI943211L (fi) 1994-09-02
US6017539A (en) 2000-01-25
US6171783B1 (en) 2001-01-09
DE69330745D1 (de) 2001-10-18
NO942530D0 (no) 1994-07-05
US20080312412A1 (en) 2008-12-18
US20080027213A1 (en) 2008-01-31
US5968776A (en) 1999-10-19
RU2123047C1 (ru) 1998-12-10
US7244589B2 (en) 2007-07-17
US6033668A (en) 2000-03-07
NO942530L (no) 1994-09-05
WO1993014207A1 (en) 1993-07-22
US20050136067A1 (en) 2005-06-23
AU3340293A (en) 1993-08-03
CA2126863C (en) 1999-08-10
AU667502B2 (en) 1996-03-28
EP0621898A1 (de) 1994-11-02

Similar Documents

Publication Publication Date Title
DK0621898T3 (da) Kimæriske immunogener
KR900700508A (ko) 인간의 호흡기 합포체성 바이러스에 대한 당단백질 면역 단편을 함유하는 키메라(chimeric) 당단백질
DK0853487T3 (da) Neutraliserende monoklonale antistoffer mod respiratorisk syncytial virus
ATE267258T1 (de) Impfstoffe für das respiratorische-synzytial- virus mit nuklein säuren
DK0759067T3 (da) Transformerende vækstfaktor alfa-H1
DK0612250T3 (da) Fremgangsmåder og præparater med relation til nyttige Moraxella catarrhalis-antigener
DK251890A (da) Polypeptid og dets anvendelse samt ekspressionssystem til dets eksprimering
CA2231603A1 (en) Chicken interleukin-15 and uses thereof
DK22389D0 (da) Fremgangsmaade og middel til beskyttelse mod sygdomme foraarsaget af mikroorganismer, navnlig mycoplasma
WO1997011093A3 (en) Parainfluenza virus glycoproteins and vaccines
BRPI9701774B8 (pt) cdna mutante e infeccioso do vírus da febre amarela, constructo de dna, vírus recombinante de febre amarela e vacina para humanos contra infecções de febre amarela.
ATE342920T1 (de) Methylierte smd homologe peptide, die mit antikörpern aus sera von lebewesen mit systemischer lupus erythematodes reagieren
ATE355375T1 (de) Bakterioferritin aus helicobacter pylori
PT817851E (pt) Dna codificador do virus do papiloma humano tipo 18
AU626684B2 (en) Mouse monoglonal antibodies for post-exposure treatment of rabies
DK482788A (da) Vacciner mod og diagnostiske bestemmelser af haemophilus influenzae
ATE248601T1 (de) Impfstoff gegen rotavirus infektionen enthaltend peptide des viralenterotoxines nsp4
DK0762895T3 (da) Syntetisk vaccine til beskyttelse mod infektion med human immundefektvirus
EP0161095A3 (de) Vakzin gegen Harninfektionen
MY101874A (en) Vaccine
HU9201590D0 (en) Recombinant vaccine against marek's illness
DK708488D0 (da) Faktor i praeparat
DK0542895T3 (da) Krydsreaktiv influenza A immunisering
DE69619123D1 (de) Hämoregulatorische verbindungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification